A favipiravir-induced angioedema and urticaria in a COVID-19 patient. Issue 6 (20th December 2022)

• Record Type: Journal Article
• Authors: Ergur Ozturk, Figen; Ozturk, Ayperi; Ates, Hale
• Is Part Of: Antiviral therapy. Volume 27:Issue 6(2022)
• Publication Date: 2022-12-20
• Subjects: Favipravir -- angioedema -- side effects; Antiviral agents -- Periodicals; Antiviral Agents -- therapeutic use; Virus Diseases -- therapy; Viruses -- drug effects; Antiviral agents; Periodical; Electronic journals; Periodicals; 616.9106
• DOI: 10.1177/13596535221146226
• Languages: English
• ISSNs: 1359-6535

Abstract

Although favipiravir is a promising drug for coronavirus disease 2019, some adverse effects, including skin lesions, have been reported. A 56-year-old female who was prescribed favipiravir by a filiation team following a positive severe acute respiratory syndrome coronavirus 2 polymerase chain reaction test presented to our hospital. After examination, favipiravir and paracetamol were prescribed. She represented to the hospital with facial swelling and itchy rashes on her forearm. Angioedema and urticaria were diagnosed. Favipiravir was discontinued. Steroid and antihistaminic therapy were administered for angioedema. To our knowledge, this is the first reported case of favipiravir-induced angioedema and urticaria in Turkey.